253 related articles for article (PubMed ID: 31631099)
1. Empagliflozin's Ameliorating Effect on Plasma Triglycerides: Association with Endothelial Function Recovery in Diabetic Patients with Coronary Artery Disease.
Sawada T; Uzu K; Hashimoto N; Onishi T; Takaya T; Shimane A; Taniguchi Y; Yasaka Y; Ohara T; Kawai H
J Atheroscler Thromb; 2020 Jul; 27(7):644-656. PubMed ID: 31631099
[TBL] [Abstract][Full Text] [Related]
2. Postprandial Glucose and Triglyceride Increases Along with the Endothelial Malfunction were Attenuated by the Administration of SGLT2 Inhibitor, Empagliflozin.
Masuda D; Yamashita S
J Atheroscler Thromb; 2020 Jul; 27(7):637-638. PubMed ID: 32009076
[No Abstract] [Full Text] [Related]
3. Effects of 6-month eicosapentaenoic acid treatment on postprandial hyperglycemia, hyperlipidemia, insulin secretion ability, and concomitant endothelial dysfunction among newly-diagnosed impaired glucose metabolism patients with coronary artery disease. An open label, single blinded, prospective randomized controlled trial.
Sawada T; Tsubata H; Hashimoto N; Takabe M; Miyata T; Aoki K; Yamashita S; Oishi S; Osue T; Yokoi K; Tsukishiro Y; Onishi T; Shimane A; Taniguchi Y; Yasaka Y; Ohara T; Kawai H; Yokoyama M
Cardiovasc Diabetol; 2016 Aug; 15(1):121. PubMed ID: 27565734
[TBL] [Abstract][Full Text] [Related]
4. Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial.
Verma S; Mazer CD; Yan AT; Mason T; Garg V; Teoh H; Zuo F; Quan A; Farkouh ME; Fitchett DH; Goodman SG; Goldenberg RM; Al-Omran M; Gilbert RE; Bhatt DL; Leiter LA; Jüni P; Zinman B; Connelly KA
Circulation; 2019 Nov; 140(21):1693-1702. PubMed ID: 31434508
[TBL] [Abstract][Full Text] [Related]
5. SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob/ob
Adingupu DD; Göpel SO; Grönros J; Behrendt M; Sotak M; Miliotis T; Dahlqvist U; Gan LM; Jönsson-Rylander AC
Cardiovasc Diabetol; 2019 Feb; 18(1):16. PubMed ID: 30732594
[TBL] [Abstract][Full Text] [Related]
6. Empagliflozin on top of metformin treatment improves arterial function in patients with type 1 diabetes mellitus.
Lunder M; Janić M; Japelj M; Juretič A; Janež A; Šabovič M
Cardiovasc Diabetol; 2018 Dec; 17(1):153. PubMed ID: 30509271
[TBL] [Abstract][Full Text] [Related]
7. Complex Positive Effects of SGLT-2 Inhibitor Empagliflozin in the Liver, Kidney and Adipose Tissue of Hereditary Hypertriglyceridemic Rats: Possible Contribution of Attenuation of Cell Senescence and Oxidative Stress.
Trnovska J; Svoboda P; Pelantova H; Kuzma M; Kratochvilova H; Kasperova BJ; Dvorakova I; Rosolova K; Malinska H; Huttl M; Markova I; Oliyarnyk O; Melcova M; Skop V; Mraz M; Stemberkova-Hubackova S; Haluzik M
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638943
[TBL] [Abstract][Full Text] [Related]
8. Sodium Glucose Co-Transporter 2 Inhibition Does Not Favorably Modify the Physiological Responses to Dietary Counselling in Diabetes-Free, Sedentary Overweight and Obese Adult Humans.
Ryan SPP; Newman AA; Wilburn JR; Rhoades LD; Trikha SRJ; Godwin EC; Schoenberg HM; Battson ML; Ewell TR; Luckasen GJ; Biela LM; Melby CL; Bell C
Nutrients; 2020 Feb; 12(2):. PubMed ID: 32085394
[TBL] [Abstract][Full Text] [Related]
9. Effect of empagliflozin on coronary microvascular function in patients with type 2 diabetes mellitus-A randomized, placebo-controlled cross-over study.
Suhrs HE; Nilsson M; Bové KB; Zander M; Prescott E
PLoS One; 2022; 17(2):e0263481. PubMed ID: 35148357
[TBL] [Abstract][Full Text] [Related]
10. Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes.
Ferrannini E; Baldi S; Frascerra S; Astiarraga B; Heise T; Bizzotto R; Mari A; Pieber TR; Muscelli E
Diabetes; 2016 May; 65(5):1190-5. PubMed ID: 26861783
[TBL] [Abstract][Full Text] [Related]
11. Effect of Sodium-Glucose Cotransport-2 Inhibitors on Blood Pressure in People With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of 43 Randomized Control Trials With 22 528 Patients.
Mazidi M; Rezaie P; Gao HK; Kengne AP
J Am Heart Assoc; 2017 May; 6(6):. PubMed ID: 28546454
[TBL] [Abstract][Full Text] [Related]
12. Effects of the Selective Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin on Vascular Function and Central Hemodynamics in Patients With Type 2 Diabetes Mellitus.
Striepe K; Jumar A; Ott C; Karg MV; Schneider MP; Kannenkeril D; Schmieder RE
Circulation; 2017 Sep; 136(12):1167-1169. PubMed ID: 28923906
[No Abstract] [Full Text] [Related]
13. Empagliflozin ameliorates endothelial dysfunction and suppresses atherogenesis in diabetic apolipoprotein E-deficient mice.
Ganbaatar B; Fukuda D; Shinohara M; Yagi S; Kusunose K; Yamada H; Soeki T; Hirata KI; Sata M
Eur J Pharmacol; 2020 May; 875():173040. PubMed ID: 32114052
[TBL] [Abstract][Full Text] [Related]
14. Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury.
Aroor AR; Das NA; Carpenter AJ; Habibi J; Jia G; Ramirez-Perez FI; Martinez-Lemus L; Manrique-Acevedo CM; Hayden MR; Duta C; Nistala R; Mayoux E; Padilla J; Chandrasekar B; DeMarco VG
Cardiovasc Diabetol; 2018 Jul; 17(1):108. PubMed ID: 30060748
[TBL] [Abstract][Full Text] [Related]
15. Determinants of the increase in ketone concentration during SGLT2 inhibition in NGT, IFG and T2DM patients.
Al Jobori H; Daniele G; Adams J; Cersosimo E; Triplitt C; DeFronzo RA; Abdul-Ghani M
Diabetes Obes Metab; 2017 Jun; 19(6):809-813. PubMed ID: 28128510
[TBL] [Abstract][Full Text] [Related]
16. Ketoacidosis Due to Empagliflozin, a Paradigm Shift: Case Report and Review of Literature.
Hernandez-Quiles C; Ramirez-Duque N; Acosta-Delgado D
Curr Diabetes Rev; 2019; 15(4):259-262. PubMed ID: 30047331
[TBL] [Abstract][Full Text] [Related]
17. Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study.
Solini A; Giannini L; Seghieri M; Vitolo E; Taddei S; Ghiadoni L; Bruno RM
Cardiovasc Diabetol; 2017 Oct; 16(1):138. PubMed ID: 29061124
[TBL] [Abstract][Full Text] [Related]
18. Impact of Sodium-Glucose Cotransporter 2 Inhibitors on Nonglycemic Outcomes in Patients with Type 2 Diabetes.
Trujillo JM; Nuffer WA
Pharmacotherapy; 2017 Apr; 37(4):481-491. PubMed ID: 28102030
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of sodium glucose cotransporter 2 inhibitors as an adjunct treatment for patients with diabetes type 2.
Pujante P; Ares J; Maciá C; Rodriguez Escobedo R; Menéndez E; Delgado E
Med Clin (Barc); 2019 Jun; 152(11):438-441. PubMed ID: 30503071
[TBL] [Abstract][Full Text] [Related]
20. Effect of tofogliflozin on cardiac and vascular endothelial function in patients with type 2 diabetes and heart diseases: A pilot study.
Tochiya M; Makino H; Tamanaha T; Matsuo M; Hishida A; Koezuka R; Ohata Y; Tomita T; Son C; Miyamoto Y; Yasuda S; Hosoda K
J Diabetes Investig; 2020 Mar; 11(2):400-404. PubMed ID: 31361403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
